A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis

NCT03151551 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

566

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriatic Arthritis

Interventions

DRUG: Ixekizumab
DRUG: Adalimumab

Sponsor

Eli Lilly and Company